Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Executive Summary
The 21st Century Cures bill made it through the US Congress in 2016 after all; advocates can thank the unexpected presidential victory of Donald Trump for helping to make that happen.
Like many prominent Republicans, House Energy & Commerce Committee Chairman Fred Upton was not excited when the party selected Donald Trump as its presidential candidate. In fact, he very publicly declined to endorse Trump ahead of the GOP convention and just as publicly called on him to drop out of the race in October after the Access Hollywood video was released.
But, now that Upton’s 21st Century Cures bill is on its way to President Obama for signature, the Michigan Republican should probably send Trump a thank-you note.
Upton launched the Cures effort in 2014 and shepherded it through the House in 2015, eager to complete work before his tenure as E&C Committee chair ends with the adjournment of the current Congress.
Heading into election day, the chances that Upton would be able to celebrate the accomplishment were looking bleak. The Senate had repeatedly missed deadlines to bring a companion bill to the floor for a vote, with the final hope a promise to take up the bill in the post-election “lame duck” session.
Find out more about Medtech Insight here
Biomedtracker: follow the drug development process
03 Apr 2017
Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.
Biomedtracker: follow the drug development process
What's on the horizon for pharma in 2018? Find out with Biomedtracker's Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.
Topics Drug development landscape
Scrip: industry news and insights
By Brian Yang
Hong Kong is catching global attention as it plans to drastically change listing rules for biotech firms, potentially opening the way to both Chinese companies seeking public funding and international firms eyeing entry to China. A Shanghai biosimilars developer, among others, is now eyeing an offering.
Topics Policy and regulation
Request a Demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Get a window into what the leading players across the biopharma, medtech, and diagnostics industries are thinking, as well as important insight into what your competitors are doing. Build your strategy with In Vivo.
In the continually evolving medtech competitive landscape, it is vital to stay up-to-date with key events. With Meddevicetracker, you’ll be able to anticipate upcoming filings, research clinical trial dates and data, and access market size information and expert forecasts, all in one place.
Looking for more products Product Finder
